Department of Health Sciences, University "Magna Græcia" of Catanzaro, Catanzaro, Italy.
Department of Experimental and Clinical Medicine, University "Magna Græcia" of Catanzaro, Catanzaro, Italy.
Front Endocrinol (Lausanne). 2022 Nov 23;13:1051988. doi: 10.3389/fendo.2022.1051988. eCollection 2022.
Germ cell tumors (GCTs) are the most common type of cancer in young men. These tumors usually originate from the testis, but they can occasionally develop from extragonadal sites probably due to primordial germ cells (PGCs) migration errors. Cisplatin-based chemotherapy is usually effective for male GCTs, but the risk of toxicity is high and new therapeutic strategies are needed. Although Metformin (Met) has been widely studied as a potential cancer treatment over the past decades, there is limited evidence to support its use in treating male GCTs. Additionally, the mechanism by which it acts on tumor cells is still not entirely understood.
SEM-1 cells, a newly established human cell line of extragonadal origin, were treated with Met. Cell viability was studied by MTT assay, while cell migration and invasion were studied by the wound healing assay and the transwell assay, respectively. The effect of Met on 3D spheroid formation was determined by seeding SEM-1 cells in appropriate cell suspension culture conditions, and cell cycle was characterized by flow cytometry. Factors involved in PGCs migration and GCT invasion, such as IGFBP1, IGF1R, MMP-11 and c-Kit, together with cyclin D1 (a key regulator of cell cycle progression), and the upstream factor, HMGA1, were determined by immunoblots.
Treatment of SEM-1 cells with Met resulted in a potent and dose-dependent reduction of cell proliferation, as evidenced by decreased nuclear abundance of cyclin D1 and cell cycle arrest in G1 phase. Also, Met prevented the formation of 3D spheroids, and blocked cell migration and invasion by reducing the expression of IGFBP1, IGF1R and MMP-11. Both, IGFBP1 and MMP-11 are under control of HMGA1, a chromatin-associated protein that is involved in the regulation of important oncogenic, metabolic and embryological processes. Intriguingly, an early reduction in the nuclear abundance of HMGA1 occurred in SEM-1 cells treated with Met.
Our results document the antiproliferative and antimigratory effects of Met in SEM-1 cells, providing new insights into the potential treatments for male GCTs. The anticancer properties of Met in SEM-1 cells are likely related to its ability to interfere with HMGA1 and downstream targets, including cyclin D1, the IGFs system, and MMP-11.
生殖细胞肿瘤(GCTs)是年轻男性中最常见的癌症类型。这些肿瘤通常起源于睾丸,但偶尔也会从性腺外部位发育,可能是由于原始生殖细胞(PGCs)迁移错误所致。基于顺铂的化疗通常对男性 GCT 有效,但毒性风险很高,需要新的治疗策略。虽然二甲双胍(Met)在过去几十年中已被广泛研究作为一种潜在的癌症治疗方法,但支持其用于治疗男性 GCT 的证据有限。此外,其作用于肿瘤细胞的机制仍不完全清楚。
使用 Met 处理新建立的人源性性腺外起源的 SEM-1 细胞系。通过 MTT 测定法研究细胞活力,通过划痕愈合测定法和 Transwell 测定法分别研究细胞迁移和侵袭。通过在适当的细胞悬浮培养条件下接种 SEM-1 细胞来确定 Met 对 3D 球体形成的影响,并通过流式细胞术对细胞周期进行表征。通过免疫印迹法确定与 PGCs 迁移和 GCT 侵袭相关的因素,如 IGFBP1、IGF1R、MMP-11 和 c-Kit,以及细胞周期进程的关键调节因子 cyclin D1 和上游因子 HMGA1。
Met 处理 SEM-1 细胞导致细胞增殖的强烈且剂量依赖性降低,这表现在 cyclin D1 的核内丰度降低和细胞周期停滞在 G1 期。此外,Met 阻止 3D 球体的形成,并通过降低 IGFBP1、IGF1R 和 MMP-11 的表达来阻止细胞迁移和侵袭。IGFBP1 和 MMP-11 均受 HMGA1 控制,HMGA1 是一种与调节重要致癌、代谢和胚胎过程相关的染色质相关蛋白。有趣的是,Met 处理的 SEM-1 细胞中 HMGA1 的核内丰度早期降低。
我们的研究结果记录了 Met 在 SEM-1 细胞中的抗增殖和抗迁移作用,为男性 GCT 的潜在治疗提供了新的见解。Met 在 SEM-1 细胞中的抗癌特性可能与其干扰 HMGA1 及其下游靶标(包括 cyclin D1、IGFs 系统和 MMP-11)的能力有关。